AIDS drugs manufacturers drop case

Today 39 pharmaceutical companies unconditionally dropped their case against the South African government. A turning point in the case may have been persuasive evidence that the companies have no economic basis for the huge prices they charge for AIDS drugs.

Written byRobert Walgate
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

LONDON South Africa's Treatment Action Campaign and its friends are crowing with delight, as 39 pharmaceutical companies this morning withdrew their lawsuit to prevent South Africa from importing inexpensive generic copies of patented AIDS drugs. They will also pay defendants' costs. The manufacturers had argued their patent rights had been infringed by the South African government three years ago. The government had claimed the AIDS epidemic is an emergency under the TRIPS international patent agreements — and so it was free to import cheap generics. The manufacturers disagreed but now they have lost the war, and won only some appalling public relations for their attitude to Third World countries.

The South African Minister of Health has assured the Treatment Action Campaign (TAC) that no concessions have been made and that the government will now proceed to implement the 'Medicines and Related Substance Control Amendment Act', which led to the companies' ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies